Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial - PubMed (original) (raw)
Clinical Trial
Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial
U Chaudhari et al. Lancet. 2001.
Abstract
Background: Currently available treatments for moderate to severe psoriasis are either incompletely effective in some patients, or are associated with toxic effects. Since tumour necrosis factor alpha (TNF-alpha) is thought to have a role in the pathogenesis of psoriasis, we did a double-blind, randomised trial to assess the clinical benefit and safety of infliximab-a monoclonal antibody against TNF-alpha.
Methods: 33 patients with moderate to severe plaque psoriasis were randomly assigned intravenous placebo (n=11), infliximab 5 mg/kg (n=11), or infliximab 10 mg/kg (n=11) at weeks 0, 2, and 6. Patients were assessed at week 10 for the primary endpoint (score on the physician's global assessment [PGA]). Analysis was by intention to treat.
Findings: Of the 33 patients enrolled, three dropped out. Nine of 11 (82%) patients in the infliximab 5 mg/kg group were responders (good, excellent, or clear rating on PGA), compared with two of 11 (18%) in the placebo group (difference 64% [95% CI 20-89], p=0.0089), and ten of 11 (91%) patients in the infliximab 10 mg/kg group were responders (difference from placebo 73% [30-94], p=0.0019). The median time to response was 4 weeks for patients in both infliximab groups. There were no serious adverse events, and infliximab was well tolerated.
Interpretation: In this controlled trial, patients receiving the anti-TNF-alpha agent infliximab as monotherapy experienced a high degree of clinical benefit and rapid time to response in the treatment of moderate to severe plaque psoriasis compared with patients who received placebo. These findings suggest that TNF-alpha has a pivotal role in the pathogenesis of psoriasis.
Similar articles
- Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial.
Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, Li S, Dooley LT, Griffiths CE; EXPRESS study investigators. Reich K, et al. Lancet. 2005 Oct 15-21;366(9494):1367-74. doi: 10.1016/S0140-6736(05)67566-6. Lancet. 2005. PMID: 16226614 Clinical Trial. - Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial.
Gottlieb AB, Evans R, Li S, Dooley LT, Guzzo CA, Baker D, Bala M, Marano CW, Menter A. Gottlieb AB, et al. J Am Acad Dermatol. 2004 Oct;51(4):534-42. doi: 10.1016/j.jaad.2004.02.021. J Am Acad Dermatol. 2004. PMID: 15389187 Clinical Trial. - Infliximab monotherapy for Chinese patients with moderate to severe plaque psoriasis: a randomized, double-blind, placebo-controlled multicenter trial.
Yang HZ, Wang K, Jin HZ, Gao TW, Xiao SX, Xu JH, Wang BX, Zhang FR, Li CY, Liu XM, Tu CX, Ji SZ, Shen Y, Zhu XJ. Yang HZ, et al. Chin Med J (Engl). 2012 Jun;125(11):1845-51. Chin Med J (Engl). 2012. PMID: 22884040 Clinical Trial. - Psoriasis and its treatment with infliximab-mediated tumor necrosis factor alpha blockade.
Winterfield L, Menter A. Winterfield L, et al. Dermatol Clin. 2004 Oct;22(4):437-47, ix. doi: 10.1016/j.det.2004.03.011. Dermatol Clin. 2004. PMID: 15450339 Review. - Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials.
Brimhall AK, King LN, Licciardone JC, Jacobe H, Menter A. Brimhall AK, et al. Br J Dermatol. 2008 Aug;159(2):274-85. doi: 10.1111/j.1365-2133.2008.08673.x. Epub 2008 Jun 10. Br J Dermatol. 2008. PMID: 18547300 Review.
Cited by
- Preliminary Investigation and Therapeutic Efficacy Determination of a Novel Anti-IL-17A Antibody, Indikizumab.
Patra AK, Nayak S, Moharana A, Ojha P, Das SK, Akhtar J, Giri B, Singh S. Patra AK, et al. Biologics. 2024 Sep 17;18:257-271. doi: 10.2147/BTT.S477752. eCollection 2024. Biologics. 2024. PMID: 39319321 Free PMC article. - Interleukin-receptor antagonist and tumour necrosis factor inhibitors for the primary and secondary prevention of atherosclerotic cardiovascular diseases.
Martí-Carvajal AJ, Gemmato-Valecillos MA, Monge Martín D, Dayer M, Alegría-Barrero E, De Sanctis JB, Parise Vasco JM, Riera Lizardo RJ, Nicola S, Martí-Amarista CE, Correa-Pérez A. Martí-Carvajal AJ, et al. Cochrane Database Syst Rev. 2024 Sep 19;9(9):CD014741. doi: 10.1002/14651858.CD014741.pub2. Cochrane Database Syst Rev. 2024. PMID: 39297531 - Serum Beta-Defensin-2 is a biomarker for psoriasis but not subclinical atherosclerosis: Role of IL17a, PI-3 kinase and Rac1.
Pantoja CJ, Li H, Rodante J, Keel A, Sorokin AV, Svedbom A, Teague HL, Stahle M, Mehta NN, Playford MP. Pantoja CJ, et al. JEADV Clin Pract. 2024 Mar;3(1):150-159. doi: 10.1002/jvc2.278. Epub 2023 Oct 27. JEADV Clin Pract. 2024. PMID: 38646149 - Chronic TNF exposure induces glucocorticoid-like immunosuppression in the alveolar macrophages of aged mice that enhances their susceptibility to pneumonia.
Kruckow KL, Murray E, Shayhidin E, Rosenberg AF, Bowdish DME, Orihuela CJ. Kruckow KL, et al. Aging Cell. 2024 Jun;23(6):e14133. doi: 10.1111/acel.14133. Epub 2024 Mar 8. Aging Cell. 2024. PMID: 38459711 Free PMC article. - The Pathophysiology and Treatment of Pyoderma Gangrenosum-Current Options and New Perspectives.
Łyko M, Ryguła A, Kowalski M, Karska J, Jankowska-Konsur A. Łyko M, et al. Int J Mol Sci. 2024 Feb 19;25(4):2440. doi: 10.3390/ijms25042440. Int J Mol Sci. 2024. PMID: 38397117 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical